|Trade names||Zyprexa, others|
|by mouth, intramuscular|
|Metabolism||Hepatic (direct glucuronidation and CYP1A2 mediated oxidation)|
|Biological half-life||33 hours, 51.8 hours (elderly)|
|Excretion||Urine (57%; 7% as unchanged drug), faeces (30%)|
|Chemical and physical data|
|3D model (JSmol)|
|Melting point||195 °C (383 °F)|
|Solubility in water||Practically insoluble in water mg/mL (20 °C)|
|(what is this?)|
Olanzapine (originally branded Zyprexa) is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is usually classed with the atypical antipsychotics, the newer generation of antipsychotics. It appears to have slightly greater effectiveness in treating schizophrenia (especially the negative symptoms) and a lower risk of causing movement disorders than typical antipsychotics. Olanzapine, however, has a higher risk of causing metabolic side effects like weight gain and type 2 diabetes than the typical antipsychotics.
Olanzapine is structurally similar to clozapine and quetiapine. It is chemically classified as a thienobenzodiazepine. It is believed to work by blocking, or antagonizing, the dopamine D2 receptor which is an action it shares with all presently-approved antipsychotics. Like most other atypical antipsychotics olanzapine also strongly antagonizes the 5-HT2A receptor, which may partially underpin its reduced propensity for causing movement disorders. Despite its close structural relation to traditional benzodiazepine anxiety-relieving medications, it possesses no affinity for the GABAA receptor, its anxiety-relieving effect is mediated through its effect on dopamine and 5-HT receptors.
- 1 Medical uses
- 2 Adverse effects
- 3 Pharmacology
- 4 Metabolism
- 5 Society and culture
- 6 Research
- 7 References
- 8 External links
The first-line psychiatric treatment for schizophrenia is antipsychotic medication which includes olanzapine. Olanzapine appears effective in reducing symptoms of schizophrenia, treating acute exacerbations, and treating early-onset schizophrenia. The usefulness of maintenance therapy, however, is difficult to determine as more than half of people in trials quit before the six-week completion date. Olanzapine treatment may result in increased weight gain and increased glucose and cholesterol levels when compared to most other second-generation antipsychotic drugs used to treat schizophrenia, other than clozapine.
National Institute for Health and Care Excellence, the British Association for Psychopharmacology, and the World Federation of Societies for Biological Psychiatry suggest that there is little difference in effectiveness between antipsychotics in prevention of relapse, and recommend that the specific choice of antipsychotic be chosen based on persons preference and side effect profile. The U.S. Agency for Healthcare Research and Quality concludes that olanzapine is not different from haloperidol in the treatment of positive symptoms and general psychopathology, or in overall assessment, but that it is superior for the treatment of negative and depressive symptoms. When trials enrolling only treatment-resistant patients were excluded from the analysis, olanzapine was superior for overall assessment.
In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, olanzapine was ranked third, demonstrating strong effectivity. Less effective than clozapine, slightly more effective than risperidone and paliperidone, and more effective than haloperidol, quetiapine, and aripiprazole. A 2013 review of first episode schizophrenia concluded that olanzapine is superior to haloperidol in providing a lower discontinuation rate, and in short-term symptom reduction, response rate, negative symptoms, depression, cognitive function, discontinuation due to poor efficacy, and long-term relapse, but not in positive symptoms or on the Clinical Global Impressions score. In contrast, pooled second generation antipsychotics showed superiority to first generation antipsychotics only against the discontinuation, negative symptoms (with a much larger effect seen among industry- compared to government-sponsored studies), and cognition scores. Olanzapine caused less extrapyramidal side effects, less akathisia, but caused significantly more weight gain, serum cholesterol increase, and triglyceride increase than haloperidol. A 2012 review concluded that among 10 atypical antipsychotics, only clozapine, olanzapine, and risperidone were better than first generation antipsychotics. A 2011 review concluded that neither first- nor second generation antipsychotics produce clinically meaningful changes in Clinical Global Impression scores but found that olanzapine and amisulpride produce larger effects on the PANSS and BPRS batteries than 5 other second generation antipsychotics or pooled first generation antipsychotics. A 2010 Cochrane systematic review found that olanzapine may have a slight advantage in effectiveness when compared to aripiprazole, quetiapine, risperidone and ziprasidone. No differences in effectiveness was detected when comparing olanzapine to amisulpride and clozapine.
A 2014 meta analysis of 9 published trials having minimum duration 6 months and median duration 52 weeks concluded that olanzapine, quetiapine, and risperidone had better effects on cognitive function than amisulpride and haloperidol.
Olanzapine is recommended by the National Institute of Health and Care Excellence as a first line therapy for the treatment of acute mania in bipolar disorder. Other recommended first lines are haloperidol, quetiapine and risperidone. It is recommended in combination with fluoxetine as a first line therapy for acute bipolar depression; and as a second line treatment by itself for the maintenance treatment of bipolar disorder.
The Network for Mood and Anxiety Treatments (CANMAT) recommends olanzapine as a first line maintenance treatment in bipolar disorder and the combination of olanzapine with fluoxetine as second line treatment for bipolar depression.
A 2014 meta analysis concluded that olanzapine plus fluoxetine was the most effective among nine treatments for bipolar depression included in the analysis.
Olanzapine has not been rigorously evaluated in generalized anxiety disorder, panic disorder, delusional parasitosis or post-traumatic stress disorder. Olanzapine is no less effective than lithium or valproate, and more effective than placebo in treating bipolar disorder. It has also been used for Tourette syndrome and stuttering.
Citing an increased risk of stroke, in 2004 the Committee on the Safety of Medicines (CSM) in the UK issued a warning that olanzapine and risperidone, both atypical antipsychotic medications, should not be given to elderly patients with dementia. In the U.S., olanzapine comes with a black box warning for increased risk of death in elderly patients. It is not approved for use in patients with dementia-related psychosis. However, a BBC investigation in June 2008 found that this advice was being widely ignored by British doctors.
The principal side effect of olanzapine is weight gain, which may be profound in some cases and/or associated with derangement in the blood lipid and blood sugar profiles (see section metabolic effects). A recent meta-analysis of the efficacy and tolerance of 15 antipsychotic drugs (APDs) found that it had the highest propensity for causing weight gain out of the 15 APD compared with a SMD of 0.74 Extrapyramidal side effects, although potentially serious, are infrequent to rare from olanzapine but may include tremors and muscle rigidity.
Several patient groups are at a heightened risk of side effects from olanzapine and antipsychotics in general. Olanzapine may produce non-trivial high blood sugar in people with diabetes mellitus. Likewise, the elderly are at a greater risk of falls and accidental injury. Young males appear to be at heightened risk of dystonic reactions, although these are relatively rare with olanzapine. Most antipsychotics, including olanzapine, may disrupt the body's natural thermoregulatory systems, thus permitting excursions to dangerous levels when situations (exposure to heat, strenuous exercise) occur.
Olanzapine is used therapeutically to treat serious mental illness. Occasionally it can have the opposite effect and provoke serious paradoxical reactions in a small subgroup of people, causing unusual changes in personality, thoughts or behavior; hallucinations and excessive thoughts about suicide have also been linked to olanzapine use.
Direct glucuronidation and cytochrome P450 mediated oxidation are the primary metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo. The U.S. Food and Drug Administration requires all atypical antipsychotics to include a warning about the risk of developing hyperglycemia and diabetes, both of which are factors in the metabolic syndrome. These effects may be related to the drugs' ability to induce weight gain, although there are some reports of metabolic changes in the absence of weight gain. Studies have indicated that olanzapine carries a greater risk of causing and exacerbating diabetes than another commonly prescribed atypical antipsychotic, Risperidone. Of all the atypical antipsychotics, olanzapine is one of the most likely to induce weight gain based on various measures. The effect is dose dependent in humans and animal models of olanzapine-induced metabolic side effects. There are some case reports of olanzapine-induced diabetic ketoacidosis. Olanzapine may decrease insulin sensitivity, though one 3-week study seems to refute this. It may also increase triglyceride levels.
Despite weight gain, a large multi-center randomized National Institute of Mental Health study found that olanzapine was better at controlling symptoms because patients were more likely to remain on olanzapine than the other drugs. One small, open-label, non-randomized study suggests that taking olanzapine by orally dissolving tablets may induce less weight gain, but this has not been substantiated in a blinded experimental setting.
Pregnancy and lactation
Olanzapine is associated with the highest placental exposure of any atypical antipsychotic. Despite this, the available evidence suggests it is safe during pregnancy, although the evidence is insufficiently strong to say anything with a high degree of confidence. Olanzapine is associated with weight gain which according to recent studies may put olanzapine-treated patients' offspring at a heightened risk for neural tube defects (e.g. spina bifida). Breastfeeding in women taking olanzapine is advised against due to the fact that olanzapine is secreted in breast milk with one study finding that the exposure to the infant (in mg per kg of body weight, that is) is about 1.8% that to the mother.
Olanzapine has demonstrated carcinogenic effects in multiple studies when exposed chronically to female mice and rats, but not male mice and rats. The tumors found were in either the liver or mammary glands of the animals.
The British National Formulary recommends a gradual withdrawal when discontinuing anti-psychotic treatment to avoid acute withdrawal syndrome or rapid relapse. Due to compensatory changes at dopamine, serotonin, adrenergic and histamine receptor sites in the central nervous system, withdrawal symptoms can occur during abrupt or over-rapid reduction in dosage. However, despite increasing demand for safe and effective antipsychotic withdrawal protocols or dose-reduction schedules, no specific guidelines with proven safety and efficacy are currently available. Support groups such as the Icarus Project, and other online forums provide resources and social support for those attempting to discontinue antipsychotics and other psychiatric medications. Withdrawal symptoms reported to occur after discontinuation of antipsychotics include nausea, vomiting, lightheadedness, diaphoresis, dyskinesia, orthostatic hypotension, tachycardia, nervousness, dizziness, headache, excessive non-stop crying, and anxiety. Some have argued additional somatic and psychiatric symptoms associated with dopaminergic hypersensitivity, including dyskinesia and acute psychosis, are common features of withdrawal in individuals treated with neuroleptics. Thus, some suggest the withdrawal process itself may be schizo-mimetic, producing schizophrenia-like symptoms even in previously healthy patients.
Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 450 mg, but also survival after an acute overdose of 2000 mg. There is no known specific antidote for olanzapine overdose, and even physicians are recommended to call a certified poison control center for information on the treatment of such a case. Olanzapine is considered moderately toxic in overdose; more toxic than quetiapine, aripiprazole and the SSRIs and less toxic than the MAOIs and TCAs.
Olanzapine has a higher affinity for 5-HT2A serotonin receptors than D2 dopamine receptors, which is a common property of most atypical antipsychotics, aside from the benzamide antipsychotics such as amisulpride along with the non-benzamides aripiprazole, brexpiprazole, blonanserin, cariprazine, melperone and perospirone. Olanzapine also had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study. P-glycoprotein transports a myriad of drugs across a numerous of different biological membranes (found in numerous body systems) including the blood-brain barrier (a semi-permeable membrane which filters the contents of blood prior to it reaching the brain); P-GP inhibition could mean that less brain exposure to olanzapine results from this interaction with the P-glycoprotein. A relatively large quantity of commonly encountered foods and medications inhibit P-GP, and it is fairly common for pharmaceuticals to be either substrates of P-GP, or to inhibit its action; both substrates and inhibitors of P-GP effectively increase the permeability of the blood brain barrier to P-GP substrates and subsequently increase the central activity of the substrate while reducing the local effects on the GI tract. The mediation of olanzapine in the central nervous system by P-GP means that any other substance or drug which interacts with P-GP increases the risk for toxic accumulations of both olanzapine and the other drug.
|Receptor||Ki (nM)||Biologic action and notes|
|5-HT2A||2.4||Inverse agonist. May underlie the "atypicality" of the newer antipsychotics like olanzapine. May contribute to sedating effects.|
|5-HT2C||10.2||Inverse agonist. May underlie the appetite-stimulating effects of olanzapine.|
|5-HT3||202||Antagonist. Possibly responsible, at least in part, for its antiemetic action.|
|α1A||112||Antagonist. Likely responsible for the orthostatic hypotension seen with its use.|
|M1||26||Antagonist. Likely the chief receptor responsible for the anticholinergic effects seen with olanzapine's use.|
|M3||52.67||Antagonist. Possible role in type 2 diabetes side-effects.|
|D2||3.00||Antagonist. Likely responsible for the therapeutic effects of olanzapine against the positive symptoms of schizophrenia.|
|H1||2.19||Inverse agonist. Likely responsible for the sedative effects of olanzapine.|
Olanzapine is a potent antagonist of the muscarinic M3 receptor, which may underlie its diabetogenic side effects. Additionally, olanzapine also exhibits a relatively low affinity for serotonin 5-HT1, GABAA, beta-adrenergic receptors, and benzodiazepine binding sites.
The mode of action of olanzapine's antipsychotic activity is unknown. It may involve antagonism of dopamine and serotonin receptors. Antagonism of dopamine receptors is associated with extrapyramidal effects such as tardive dyskinesia(TD), and with therapeutic effects. Antagonism of muscarinic acetylcholine receptors is associated with anticholinergic side effects such as dry mouth and constipation, in addition it may suppress or reduce the emergence of extrapyramidal effects for the duration of treatment, however it offers no protection against the development of tardive dyskinesia. In common with other second generation (atypical) antipsychotics, olanzapine poses a relatively low risk of extrapyramidal side effects including TD, due to its high affinity for the D1 receptor over the D2 receptor.
Antagonizing H1 histamine receptors causes sedation and may cause weight gain, although antagonistic actions at serotonin 5-HT2C and dopamine D2 receptors have also been associated with weight gain and appetite stimulation.
Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by 2D6. By these mechanisms more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect. Drugs or agents that increase the activity of CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of Olanzapine; conversely, drugs which inhibit 1A2 activity (examples: Ciprofloxacin, Fluvoxamine) may reduce Olanzapine clearance.
Society and culture
Olanzapine is approved in the U.S.A. by the Food and Drug Administration (FDA) for:
- Treatment — in combination with fluoxetine — of depressive episodes associated with bipolar disorder (December 2003).
- Long-term treatment — in combination with fluoxetine — of resistant depression (March 2009).
- Oral formulation: acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy and in combination with lithium or sodium valproate)
- Intramuscular formulation: acute agitation associated with schizophrenia and bipolar I mania in adults
- Oral formulation combined with fluoxetine: treatment of acute depressive episodes associated with bipolar I disorder in adults, or treatment of acute, resistant depression in adults
- Treatment of the manifestations of psychotic disorders (September 1996—March 2000).
- Short-term treatment of acute manic episodes associated with bipolar I disorder (March 2000).
- Short-term treatment of schizophrenia instead of the management of the manifestations of psychotic disorders (March 2000).
- Maintaining treatment response in schizophrenic patients who had been stable for approximately eight weeks and were then followed for a period of up to eight months (November 2000).
Controversy, prosecution, lawsuits and settlements
Eli Lilly has faced many lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa, as well as by various governmental entities, insurance companies, and others. Lilly produced a large number of documents as part of the discovery phase of this litigation, which started in 2004; the documents were ruled to be confidential by a judge and placed under seal, and later themselves became the subject of litigation.
In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits, and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion.
A December 2006 New York Times article based on leaked company documents concluded that the company had engaged in a deliberate effort to downplay olanzapine's side effects. The company denied these allegations and stated that the article had been based on cherry picked documents. The documents were provided to the Times by Jim Gottstein, a lawyer who represented mentally ill patients, who obtained them from a doctor, David Egilman, who was serving as an expert consultant on the case. In 2007 Lilly filed a protection order to stop the dissemination of some of the documents, which Judge Jack B. Weinstein of the Brooklyn Federal District Court granted, and criticized the New York Times reporter, Gottstein, and Egilman in the ruling. The Times of London also received the documents and reported that as early as 1998, Lilly considered the risk of drug-induced obesity to be a "top threat" to Zyprexa sales. On October 9, 2000, senior Lilly research physician Robert Baker noted that an academic advisory board he belonged to was "quite impressed by the magnitude of weight gain on olanzapine and implications for glucose."
Lilly had threatened Egilman with criminal contempt charges regarding the documents he took and provided to reporters; in September 2007 he agreed to pay Lilly $100,000 in return for the company’s agreement to drop the threat of charges.
In September 2008 Judge Weinstein issued an order to make public Lilly's internal documents about the drug in a different suit brought by insurance companies, pension funds, and other payors.
In March 2008 Lilly settled a suit with the state of Alaska and in October 2008, Lilly agreed to pay $62 million to 32 states and the District of Columbia to settle suits brought under state consumer protection laws.
Olanzapine is generic and is available under many trade names worldwide.
Olanzapine is marketed in a number of countries, with tablets ranging from 2.5 to 20 milligrams. Zyprexa (and generic olanzapine) is available as an orally-disintegrating "wafer" which rapidly dissolves in saliva. It is also available in 10 milligram vials for intramuscular injection.
Olanzapine has been investigated for use as an antiemetic, particularly for the control of chemotherapy-induced nausea and vomiting (CINV). A 2007 study demonstrated its successful potential for this use, achieving a complete response in the acute prevention of nausea and vomiting in 100% of patients treated with moderately and highly-emetogenic chemotherapy, when used in combination with palonosetron and dexamethasone.
Olanzapine has been considered as part of an early psychosis approach for schizophrenia. The Prevention through Risk Identification, Management, and Education (PRIME) study, funded by the National Institute of Mental Health and Eli Lilly, tested the hypothesis that olanzapine might prevent the onset of psychosis in people at very high risk for schizophrenia. The study examined 60 patients with prodromal schizophrenia, who were at an estimated risk of 36–54% of developing schizophrenia within a year, and treated half with olanzapine and half with placebo. In this study, patients receiving olanzapine did not have a significantly lower risk of progressing to psychosis. Olanzapine was effective for treating the prodromal symptoms, but was associated with significant weight gain.
- Drugs.com Drugs.com international listings for Olanzapine Page accessed August 4, 2015
- Burton, Michael E.; Shaw, Leslie M.; Schentag, Jerome J.; Evans, William E. (May 1, 2005). Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring (4th ed.). Lippincott Williams & Wilkins. p. 815. ISBN 978-0-7817-4431-7.
- "PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS" (PDF). TGA eBusiness Services. Sandoz Pty Ltd. 8 June 2012. Retrieved 26 November 2013.
- "Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 26 November 2013.
- "Olanzapine Prescribing Information" (PDF). Eli Lilly and Company. 2009-03-19. Retrieved 2009-09-06.
- Leucht, Stefan; Cipriani, Andrea; Spineli, Loukia; Mavridis, Dimitris; Orey, Deniz; Richter, Franziska; Samara, Myrto; Barbui, Corrado; Engel, Rolf R. (2013-09-14). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. ISSN 1474-547X. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3.
- Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
- Taylor, D; Paton, C; Kapur, S (2015). The Maudsley Prescribing Guidelines in Psychiatry (12th ed.). London, UK: Wiley-Blackwell. p. 16. ISBN 978-1-118-75460-3.
- "Lilly 2008 Annual Report" (PDF). Lilly. 2009. Retrieved 2009-08-06.
- National Collaborating Centre for Mental Health (25 March 2009). "Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care" (PDF). Retrieved 25 November 2009.
- Harvey, Rebecca C.; James, Anthony C.; Shields, Gemma E. (January 2016). "A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia". CNS drugs. 30 (1): 27–39. ISSN 1179-1934. PMID 26801655. doi:10.1007/s40263-015-0308-1.
- Pagsberg, Anne Katrine; Tarp, Simon; Glintborg, Dorte; Stenstrøm, Anne Dorte; Fink-Jensen, Anders; Correll, Christoph Ulrich; Christensen, Robin (March 2017). "Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis". Journal of the American Academy of Child and Adolescent Psychiatry. 56 (3): 191–202. ISSN 1527-5418. PMID 28219485. doi:10.1016/j.jaac.2016.12.013.
- Osser DN, Roudsari MJ, Manschreck T (2013). "The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia". Harv Rev Psychiatry. 21 (1): 18–40. PMID 23656760. doi:10.1097/HRP.0b013e31827fd915.
- Duggan, L.; Fenton, M.; Rathbone, J.; Dardennes, R.; El-Dosoky, A.; Indran, S. (2005-04-18). "Olanzapine for schizophrenia". The Cochrane Database of Systematic Reviews (2): CD001359. ISSN 1469-493X. PMID 15846619. doi:10.1002/14651858.CD001359.pub2.
- Komossa, Katja; Rummel-Kluge, Christine; Hunger, Heike; Schmid, Franziska; Schwarz, Sandra; Duggan, Lorna; Kissling, Werner; Leucht, Stefan (2010-03-17). "Olanzapine versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews (3): CD006654. ISSN 1469-493X. PMC . PMID 20238348. doi:10.1002/14651858.CD006654.pub2.
- "Psychosis and schizophrenia in adults: treatment and management | Guidance and guidelines | NICE". National Institute for Health and Care Excellence.
- Barnes TR (2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". J. Psychopharmacol. (Oxford). 25 (5): 567–620. PMID 21292923. doi:10.1177/0269881110391123.
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ (2013). "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects". World J. Biol. Psychiatry. 14 (1): 2–44. PMID 23216388. doi:10.3109/15622975.2012.739708.
- Abou-Setta, AM; Mousavi, SS; Spooner, C; Schouten, JR; Pasichnyk, D; Armijo-Olivo, S; Beaith, A; Seida, JC; Dursun, S; Newton, AS; Hartling, L (August 2012). "First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]". PMID 23035275.
- Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (July 2013). "Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis". Int. J. Neuropsychopharmacol. 16 (6): 1205–18. PMC . PMID 23199972. doi:10.1017/S1461145712001277.
- Citrome L (August 2012). "A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia". Expert Opin Pharmacother. 13 (11): 1545–73. PMID 21999805. doi:10.1517/14656566.2011.626769.
- Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (May 2011). "Clinical relevance of findings in trials of antipsychotics: systematic review". Br J Psychiatry. 198 (5): 341–5. PMID 21525517. doi:10.1192/bjp.bp.109.075366.
- Désaméricq G, Schurhoff F, Meary A, et al. (February 2014). "Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis". Eur. J. Clin. Pharmacol. 70 (2): 127–34. PMID 24145817. doi:10.1007/s00228-013-1600-y.
- "Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care | 1-recommendations | Guidance and guidelines | NICE". Retrieved 26 July 2016.
- Yatham LN, Kennedy SH, O'Donovan C, et al. (December 2006). "Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007". Bipolar Disord. 8 (6): 721–39. PMID 17156158. doi:10.1111/j.1399-5618.2006.00432.x.
- Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ (March 2014). "Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics". Pharmacopsychiatry. 47 (2): 43–52. PMID 24549862. doi:10.1055/s-0033-1363258.
- Maglione M, Maher AR, Hu J, et al. (2011). "Off-Label Use of Atypical Antipsychotics: An Update". PMID 22132426.
- Narasimhan M, Bruce TO, Masand P (October 2007). "Review of olanzapine in the management of bipolar disorders". Neuropsychiatr Dis Treat. 3 (5): 579–587. PMC . PMID 19300587.
- Scott, Lisa (Winter 2006). "Genetic and Neurological Factors in Stuttering". Stuttering Foundation of America.
- "Important Safety Information for Olanzapine". Zyprexa package insert. Eli Lilly & Company. 2007. Archived from the original on 2007-11-23. Retrieved 2007-12-03.
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.
- "Doctors 'ignoring drugs warning'". BBC News. 17 June 2008. Retrieved 2008-06-22.
- Lexi-Comp Inc. (2010) Lexi-Comp Drug Information Handbook 19th North American Ed. Hudson, OH: Lexi-Comp Inc. ISBN 978-1-59195-278-7.
- Stöllberger C.; Lutz W.; Finsterer J. (2009). "Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities". European Journal of Neurology. 16: 879–882. doi:10.1111/j.1468-1331.2009.02581.x.
- "OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]". DailyMed. Prasco Laboratories. September 2013. Retrieved 26 November 2013.
- "Olanzapine 10 mg tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Aurobindo Pharma - Milpharm Ltd. 17 May 2013. Retrieved 26 November 2013.
- "Olanzapine Monograph for Professionals - Drugs.com". Drugs.com. Retrieved 24 March 2017.
- Cerner Multum Incorporated (27 September 2011). "Olanzapine". Drugs.com.
- Ramankutty G (2002). "Olanzapine-induced destabilization of diabetes in the absence of weight gain". Acta Psychiatrica Scandinavica. 105 (3): 235–6; discussion 236–7. PMID 11939979. doi:10.1034/j.1600-0447.2002.2c257a.x.
- Lambert MT, Copeland LA, Sampson N, Duffy SA (2006). "New-onset type-2 diabetes associated with atypical antipsychotic medications". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 (5): 919–23. PMID 16581171. doi:10.1016/j.pnpbp.2006.02.007.
- Moyer, Paula (Oct 25, 2005). "CAFE Study Shows Varying Benefits Among Atypical Antipsychotics". Medscape Medical News. WebMD. Retrieved 2007-12-03.
- AstraZeneca Pharmaceuticals (4 April 2006). "Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison". AstraZeneca Clinical Trials. AstraZeneca PLC. Archived from the original on 2007-11-13. Retrieved 2007-12-03.
At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).
- Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999). "Novel Antipsychotics". The Journal of Clinical Psychiatry. 60 (6): 358–63. PMID 10401912. doi:10.4088/JCP.v60n0602.
- "NIMH study to guide treatment choices for schizophrenia" (Press release). National Institute of Mental Health. 19 September 2005. Retrieved 2006-12-18.
- McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007). "Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison". American Journal of Psychiatry. 164 (7): 1050–60. PMID 17606657. doi:10.1176/ajp.2007.164.7.1050.
- Nemeroff CB (1997). "Dosing the antipsychotic medication olanzapine". The Journal of Clinical Psychiatry. 58 (Suppl 10): 45–9. PMID 9265916.
- Fulbright, A. R.; Breedlove, K. T. (2006). "Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis". Journal of Pharmacy Practice. 19 (4): 255–8. doi:10.1177/0897190006294180.
- Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML (2010). "The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 34 (6): 866–70. PMID 20394794. doi:10.1016/j.pnpbp.2010.04.003.
- Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Müller M, Kasper S (2007). "Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers". Neuropsychopharmacology. 33 (7): 1633–41. PMID 17712347. doi:10.1038/sj.npp.1301541.
- Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J (2003). "Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp". Journal of Clinical Endocrinology & Metabolism. 88 (12): 5875–80. PMID 14671184. doi:10.1210/jc.2002-021884.
- Carey, Benedict (September 20, 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved 2007-12-03.
- de Haan L, van Amelsvoort T, Rosien K, Linszen D (2004). "Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets". Psychopharmacology. 175 (3): 389–90. PMID 15322727. doi:10.1007/s00213-004-1951-2.
- Taylor, D. The Maudsley prescribing guidelines in psychiatry. Wiley-Blackwell.
- Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J (June 2008). "Maternal obesity and risk of neural tube defects: a metaanalysis". American Journal of Obstetrics & Gynecology. 198 (6): 611–619. PMID 18538144. doi:10.1016/j.ajog.2008.04.021.
- McMahon DM, Liu J, Zhang H, Torres ME, Best RG (February 2013). "Maternal obesity, folate intake, and neural tube defects in offspring". Birth Defects Research Part A: Clinical and Molecular Teratology. 97 (2): 115–122. PMID 23404872. doi:10.1002/bdra.23113.
- Brambilla G, Mattioli F, Martelli A (2009). "Genotoxic and carcinogenic effects of antipsychotics and antidepressants". Toxicology. 261 (3): 77–88. PMID 19410629. doi:10.1016/j.tox.2009.04.056.
- "4.2.1 Antipsychotic drugs". British National Formulary (57th ed.). London and Chicago: Pharmaceutical Press. March 2009. pp. 221–31. ISBN 978-0-85711-065-7.
Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
- "Harm Reduction Guide To Coming Off Psychiatric Drugs & Withdrawal". Icarus Project. April 23, 2008.
- Kim DR, Staab JP (2005). "Quetiapine Discontinuation Syndrome". American Journal of Psychiatry. 162 (5): 1020. PMID 15863814. doi:10.1176/appi.ajp.162.5.1020.
- Michaelides C, Thakore-James M, Durso R (2005). "Reversible withdrawal dyskinesia associated with quetiapine". Movement Disorders. 20 (6): 769–70. PMID 15747370. doi:10.1002/mds.20427.
- Chouinard G, Jones BD (1980). "Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics". The American Journal of Psychiatry. 137 (1): 16–21. PMID 6101522.
- Miller R, Chouinard G (1993). "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia". Biological Psychiatry. 34 (10): 713–38. PMID 7904833. doi:10.1016/0006-3223(93)90044-E.
- Chouinard G, Jones BD, Annable L (1978). "Neuroleptic-induced supersensitivity psychosis". The American Journal of Psychiatry. 135 (11): 1409–10. PMID 30291.
- Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'dowd BF, George SR, Perreault ML, Männistö PT, Robinson S, Palmiter RD, Tallerico T (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proceedings of the National Academy of Sciences. 102 (9): 3513–8. Bibcode:2005PNAS..102.3513S. JSTOR 3374957. PMC . PMID 15716360. doi:10.1073/pnas.0409766102.
- Moncrieff J (2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. PMID 16774655. doi:10.1111/j.1600-0447.2006.00787.x.
- "Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information". RxList: The Internet Drug Index. WebMD. 2007. Retrieved 2007-12-03.
- Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL (September 2006). "Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein". Psychopharmacology (Berl). 187 (4): 415–423. PMID 16810505. doi:10.1007/s00213-006-0437-9.
- Moons T, de Roo M, Claes S, Dom G (August 2011). "Relationship between P-glycoprotein and second-generation antipsychotics". Pharmacogenomics. 12 (8): 1193–1211. PMID 21843066. doi:10.2217/pgs.11.55.
- John R. Horn, PharmD, FCCP, and Philip Hansten, PharmD (December 1, 2008). "Drug Transporters: The Final Frontier for Drug Interactions". Pharmacy Times.
- Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 8 November 2013. Retrieved 26 November 2013.
- Weston-Green K, Huang XF, Deng C (10 October 2013). "Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor". CNS Drugs. 27: 1069–1080. PMID 24114586. doi:10.1007/s40263-013-0115-5. Retrieved 15 February 2014.
- Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H (2005). "Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion from Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia". Diabetes. 54 (5): 1552–8. PMID 15855345. doi:10.2337/diabetes.54.5.1552.
- Silvestre JS, Prous J (2005). "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes". Methods and Findings in Experimental and Clinical Pharmacology. 27 (5): 289–304. PMID 16082416. doi:10.1358/mf.2005.27.5.908643.
- "olanzapine". NCI Drug Dictionary. National Cancer Institute.
- Lemke TL, Williams DA (2009) Foye's Medicinal Chemistry, 6th edition. Wolters Kluwer: New Delhi. ISBN 978-81-89960-30-8.
- "Medication and Weight Control"
- "NDA 21-520" (PDF). Food and Drug Administration. 2003-12-24. Retrieved 2009-09-06.
- "NDA 20-592 / S-019" (PDF). Food and Drug Administration. 2004-01-14. Retrieved 2009-09-06.
- Pillarella J, Higashi A, Alexander GC, Conti R (2012). "Trends in the use of atypical antipsychotics for the treatment of bipolar disorder in the United States, 1998-2009". Psychiatric Services. 63 (1): 83–86. PMC . PMID 22227765. doi:10.1176/appi.ps.201100092.
- Forbes.com[dead link]
- treatment resistant depression defined as major depressive disorder in adult patients who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode
- "NDA 20-592" (PDF). Food and Drug Administration. 1996-09-06. Retrieved 2009-09-06.
- "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa". U.S. Justice Department. 2009-01-15. Retrieved 2012-07-09.
- Walsh, Mary Williams (5 September 2008). "Judge to Unseal Documents on the Eli Lilly Drug Zyprexa". The New York Times.
- Berenson, Alex (January 4, 2007). "Mother Wonders if Psychosis Drug Helped Kill Son". The New York Times. Retrieved May 21, 2013.
- Berenson, Alex (5 January 2007). "Lilly Settles With 18,000 Over Zyprexa". The New York Times.
- Pagnamenta, Robin (January 23, 2007). "Eli Lilly was concerned by Zyprexa side-effects from 1998". The Times (London). Archived from the original on February 20, 2007.
- Berenson, Alex (December 17, 2006). "Eli Lilly Said to Play Down Risk of Top Pill". The New York Times. Retrieved May 21, 2013.
- Harris, Gardiner; Berenson, Alex (14 January 2009). "Lilly Said to Be Near $1.4 Billion U.S. Settlement". The New York Times.
- Berenson, Alex (26 March 2008). "Lilly Settles Alaska Suit Over Zyprexa". The New York Times.
- MSN.com Lilly settles Zyprexa suit for $1.42 billion.
- Berenson, Alex (December 18, 2006). "Drug Files Show Maker Promoted Unapproved Use". The New York Times. Retrieved May 21, 2013.
- Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007). "A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study". Supportive Care in Cancer. 15 (11): 1285–91. PMID 17375339. doi:10.1007/s00520-007-0248-5.
- McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A (2003). "The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis". Schizophrenia Research. 61 (1): 7–18. PMID 12648731. doi:10.1016/S0920-9964(02)00439-5.
- McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006). "Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis". American Journal of Psychiatry. 163 (5): 790–9. PMID 16648318. doi:10.1176/appi.ajp.163.5.790.
|Wikimedia Commons has media related to Olanzapine.|